{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.7","value":"804.791"},{"groupId":"OG001","spread":"20.5","value":"1072.850"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"1 year to \\< 10 years pediatric patients","id":"OG000","title":"Group 1"},{"description":"\\>= 10 years to \\<18 years pediatric patients","id":"OG001","title":"Group 2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Analysis Set (PAS) consists of all patients who received the nilotinib dose on Day 1, had an evaluable Day 1 PK profile or provided at least one evaluable steady state trough concentration.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 8 - Cycle 1 Day 28","title":"Summary of Nilotinib Steady-state PK Parameters: Cmin","type":"PRIMARY","unitOfMeasure":"ng/mL"}